About 347 million people worldwide have diabetes.1 In many cases this leads to perihperal artery disease.
"The high prevalance of chronic renal impairment in diabetic patients with PAD and the need for high doses of gadolinium based contrast agents place them at risk for nephrogenic system fibrosis."2
QISS3 provides an accurate non-contrast alternativeto CE-MRA for demonstrating clinically significant arterial disease in patients where contrast agents are contraindicated.2,4 Enhance clinical capabilities with access to latest clinical standards of care and improve patient safety with the reduced need for CE-MRA.
"QISS MRA should become the non-contrast MRA technique of choice in patients with renal dysfunction."5
Maria Carr, Research Technologist Northwestern University Feinberg School of Medicine Chicago, US
Quiescent-Interval Single-Shot Unenhanced Magnetic Resonance Angiography of Peripheral Vascular Disease: Technical Considerations and Clinical Feasibility
Peripheral arterial disease in a symptomatic diabetic population: prospective comparison of rapid unenhanced MR angiography (MRA) with contrast-enhanced MRA.
Nonenhanced peripheral MR-angiography (MRA) at 3 Tesla: evaluation of quiescent-interval single-shot MRA in patients undergoing digital subtraction angiography.
Nonenhanced ECG-Gated Quiescent-Interval Single Shot MRA: Image Quality and Stenosis Assessment at 3 Tesla Compared With Contrast-Enhanced MRA and Digital Subtraction Angiography
5
Siemens'in müşterileri hakkındaki açıklamalar müşterinin kendi ortamlarında aldıkları sonuçlara dayanmaktadır. "Tipik" bir hastane tanımı olmadığından ve pek çok değişken mevcut olduğundan (örn. hastane büyüklüğü, vaka karması, bilişim teknolojileri benimseme seviyeleri) diğer müşterilerin aynı sonuçları elde edeceğinin garantisi yoktur.
